Kinoshita M, Mikuni Y, Kudo M, Mori M, Horie E, Teramoto T, Matsushima T
Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
J Int Med Res. 2002 May-Jun;30(3):271-81. doi: 10.1177/147323000203000308.
In the present study, we evaluated the effects of combination therapy with niceritrol and pravastatin in patients with hyperlipidaemia. A total of 62 patients with hyperlipidaemia, defined as total cholesterol levels above 220 mg/dl or triglyceride levels above 150 mg/dl, were recruited. Patients were divided into two groups: Group N received initial therapy with niceritrol 750-1500 mg/day, and those in Group P, pravastatin 10 mg/day. After 8 weeks, pravastatin 10 mg/day was added to the Group N treatment regimen for a further 8 weeks, while patients in Group P were given niceritrol 750-1500 mg/day in addition to pravastatin for 8 weeks. After the 8-week combination therapy study period, total cholesterol levels were 209.6 mg/dl in Group N and 220.7 mg/dl in Group P. Decreased triglyceride and lipoprotein(a) levels and increased high-density lipoprotein cholesterol levels, neither of which were achieved by pravastatin administration alone, were achieved with the combination of pravastatin and niceritrol. We conclude that when a single lipid-lowering drug fails to show therapeutic value, attempting combination therapy with a nicotinic acid preparation and a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) is worthwhile.
在本研究中，我们评估了尼可占替诺与普伐他汀联合治疗对高脂血症患者的影响。共招募了62例高脂血症患者，定义为总胆固醇水平高于220mg/dl或甘油三酯水平高于150mg/dl。患者分为两组：N组初始接受尼可占替诺750 - 1500mg/天治疗，P组患者接受普伐他汀10mg/天治疗。8周后，N组治疗方案中加用普伐他汀10mg/天，持续8周，而P组患者在普伐他汀基础上加用尼可占替诺750 - 1500mg/天，持续8周。在为期8周的联合治疗研究期结束后，N组总胆固醇水平为209.6mg/dl，P组为220.7mg/dl。普伐他汀与尼可占替诺联合使用可降低甘油三酯和脂蛋白(a)水平，并提高高密度脂蛋白胆固醇水平，而单独使用普伐他汀无法达到这些效果。我们得出结论，当单一降脂药物未能显示出治疗价值时，尝试使用烟酸制剂与3 - 羟基 - 3 - 甲基戊二酰辅酶A还原酶抑制剂（他汀类药物）进行联合治疗是值得的。
